TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A study of 230 autopsy cases found higher rates of Alzheimer’s amyloid pathology in women with Parkinson’s disease, particularly women with Parkinson’s disease dementia. Researchers found no sex difference in tau pathology or levels of cognitive impairment; whether the finding could guide treatment research remains unknown.
A study of 230 autopsy cases found that women with Parkinson’s disease had higher rates of Alzheimer’s amyloid pathology than men, with the difference particularly evident among women with Parkinson’s disease dementia. Published in the Journal of Parkinson’s Disease, the research adds evidence that brain changes associated with different neurodegenerative diseases can occur together, but it does not establish that amyloid caused dementia or that Alzheimer’s treatments benefit people with Parkinson’s.
Researchers examined autopsy cases from the Arizona Study of Aging and Neurodegenerative Disorders and its Brain and Body Donation Program. The study compared findings in women and men who had Parkinson’s disease, looking for differences in associated brain pathologies. Its central reported result was a greater burden of Alzheimer’s amyloid pathology in women, particularly in the subgroup with Parkinson’s disease dementia.
Amyloid is a protein that can accumulate in plaques in the brain; such plaques are among the brain changes associated with Alzheimer’s disease. The researchers also assessed tau pathology and cognitive impairment. According to the report, they found no difference between women and men in either tau pathology or levels of cognitive impairment. The findings therefore concern amyloid pathology specifically, rather than a general increase across all Alzheimer’s-related measures.
The study was led by researchers including Erika Driver-Dunckley, M.D., a movement disorder neurologist at Mayo Clinic. The published paper is titled “Greater burden of Alzheimer’s Co-pathology in women with Parkinson’s disease dementia.” It appeared in the journal’s 2026 volume, pages 1191–1200, with DOI 10.1177/1877718X261470295.
What Amyloid Findings Could Mean
The result may help researchers investigate why some people with Parkinson’s also have changes associated with Alzheimer’s, and whether those overlapping pathologies relate to differences between women and men. It also reinforces that a clinical diagnosis does not necessarily capture every disease process present in the brain: in this study, autopsy examination identified Alzheimer’s-related pathology alongside Parkinson’s.
That distinction matters for future research. If amyloid contributes to symptoms for some people with Parkinson’s disease dementia, identifying that subgroup could help scientists test whether treatments aimed at amyloid have a role. But this study did not test treatment, measure whether amyloid removal improves symptoms, or show that the pathology explains the observed sex difference. The suggestion of a possible treatment-research direction is a question for future studies, not a recommendation for patients.
Some anti-amyloid medicines are approved for certain people diagnosed with Alzheimer’s disease, according to the report. Their approval for those patients does not establish that they are effective or appropriate for Parkinson’s disease dementia. People should not change care based on this autopsy finding; medical decisions require discussion with a qualified clinician.
Products Worth Considering
Levoit Core 400S-P Smart Air Purifier for Large Rooms
LEVOIT Vital 200S-P Smart Air Purifier for Large Rooms
Hyperice Hypervolt 3 Percussion Massage Gun with Heated Head and Carry Case
As an affiliate, we earn on qualifying purchases.
How Parkinson’s and Alzheimer’s Overlap
The study addresses co-pathology: more than one type of disease-related change found in the same brain. People entering a brain donation program may have had a clinical diagnosis of Parkinson’s, while later autopsy findings reveal additional pathology. The researchers said mixed pathologies are not unusual in their work; what drew their attention here was the reported difference between women and men.
The research used the Arizona program’s donated brain material, allowing investigators to examine pathology directly after death. That design can show which changes were present in the examined brains, but it cannot by itself establish when those changes developed, how they affected a person over time, or whether they caused particular symptoms. The study’s conclusion is about an association observed in this set of cases.
““What we found was, in women, particularly those with Parkinson’s disease dementia, they had higher rates of Alzheimer’s amyloid pathology.””
— Erika Driver-Dunckley, M.D., Mayo Clinic movement disorder neurologist and one of the lead researchers
Limits of the Autopsy Findings
The report does not provide enough detail to establish how large the difference was, how many participants were in each sex or dementia subgroup, or how the cases were selected beyond their inclusion in the Arizona study and donation program. The findings come from 230 autopsy cases, not a population-wide sample, so they should not be treated as estimates of amyloid prevalence among all women and men with Parkinson’s.
Autopsy observations also cannot show that amyloid caused Parkinson’s disease dementia, explain why the sex difference appeared, or determine whether it affects disease progression during life. The reported absence of a sex difference in tau pathology and cognitive impairment further means the results do not point to a broad difference across every measure examined. The study does not report a clinical trial or evidence that anti-amyloid medicines help people with Parkinson’s disease dementia.
Questions for Future Treatment Studies
The immediate next step is further research to determine whether the finding appears in other groups of people with Parkinson’s and whether amyloid pathology is linked to particular symptoms or outcomes. Studies with larger or independently assembled samples could test how consistent the sex difference is and clarify how Parkinson’s, dementia, and Alzheimer’s-related changes overlap.
Researchers may also investigate whether people with Parkinson’s disease dementia and elevated amyloid respond differently to treatments that target amyloid. Driver-Dunckley said the findings raise the possibility of studying whether such treatments could someday benefit some patients with Parkinson’s disease dementia who also have increased amyloid pathology. Whether that research will take place, and what it might show, remains uncertain; no treatment benefit was established by this study.
Key Questions
What did the study find?
Among 230 autopsy cases of people with Parkinson’s disease, researchers reported higher rates of Alzheimer’s amyloid pathology in women, particularly women with Parkinson’s disease dementia.
No. The report says researchers found no difference between women and men in tau pathology or levels of cognitive impairment. The reported difference was in amyloid pathology.
Does this show amyloid causes dementia in women with Parkinson’s?
No. The study found an association in autopsy cases. It does not establish that amyloid caused dementia or explain why the difference appeared.
Could Alzheimer’s drugs help people with Parkinson’s disease dementia?
The study did not test medicines or demonstrate a treatment benefit. Researchers said the result could inform future research into whether anti-amyloid treatments might help a subset of patients. Patients should consult a qualified medical professional about care.
Source: news-medical.net
